Thank you everyone for this interesting discussion. I am very impressed by the significant reduction of the LDL cholesterol level by Evinacumab and excited to follow the results of a phase III trial comparing the drug with the standard of care treatment. When comparing the population clinical characteristics I noticed a significant difference between lipoprotein (a) levels between groups, especially in the subcutaneous group. Do you think that differences in the median of lipoprotein(a) levels may have any effect on the results?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.